Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed topline results from the Phase 3 clinical trial evaluating Zepzelca (lurbinectedin) in combination with the PD-L1 inhibitor Roche Holdings AG’s ...
Zacks Investment Research on MSN
JAZZ’s Zepzelca fails to meet primary goal in lung cancer study
Shares of Jazz Pharmaceuticals JAZZ fell more than 2% on Friday after the company announced disappointing results from a ...
(Reuters) -The U.S. Food and Drug Administration has approved Jazz Pharmaceuticals' combination therapy as a maintenance treatment for adult patients with a type of lung cancer, the regulator said on ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results